Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS –lidocaine vs bupivacaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine showed no clear difference in presence of any TNS – lidocaine vs 2‐chloroprocaine compared with other local anaesthetic (low certainty).
Risk of transient neurological symptoms with spinal lidocaine may leads to lower presence of any TNS – lidocaine vs levobupivacaine compared with other local anaesthetic (low certainty).
It is very uncertain whether risk of transient neurological symptoms with spinal lidocaine changes presence of any TNS – lidocaine vs mepivacaine compared with other local anaesthetic (very low certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS – lidocaine vs prilocaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine probably leads to lower presence of any TNS – lidocaine vs procaine compared with other local anaesthetic (moderate certainty).
Risk of transient neurological symptoms with spinal lidocaine may leads to lower presence of any TNS – lidocaine vs ropivacaine compared with other local anaesthetic (low certainty).
It is very uncertain whether early discontinuation of antibiotic treatment changes any bacteraemia compared with treatment until neutropenia resolution (very low certainty).
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
RISPERIDONE showed no clear difference in leaving the study early: 1. any reason, long term (>12 months) compared with QUETIAPINE ‒ short‐ and long‐term data (low certainty).
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
It is very uncertain whether RISPERIDONE changes adverse effects. 1. Movement disorders ‐ any extrapyramidal compared with CLOZAPINE ‐ all data short term (very low certainty).
It is very uncertain whether RISPERIDONE changes leaving the study early ‒ any reason compared with CLOZAPINE ‐ all data short term (very low certainty).
The intervention showed no clear difference in number of participants who received additional medical consultant… (low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
The intervention leads to lower any adverse events 49 weeks (high certainty).